Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Market Cap | Price | Price Target | Upside/Downside | Top Analysts Upside/Downside | Consensus | Top Analysts Consensus | Analysts | Top Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARGX | ARGENX SE | $35.46B | $583.66 | $721.36 | 23.59% | Strong Buy | 14 | 970.77% | 24.46% | 38.50% | 34.13% | |||
| AUPH | AURINIA PHARMACEUTICALS INC | $1.17B | $8.52 | N/A | N/A | N/A | N/A | 24.09% | 213.21% | 64.76% | 44.40% | |||
| TGTX | TG THERAPEUTICS INC | $6.41B | $40.79 | $42.50 | 4.19% | Strong Buy | 4 | 41.33% | 151.26% | 282.55% | 108.76% | |||
| CORT | CORCEPT THERAPEUTICS INC | $6.03B | $57.11 | $99.75 | 74.66% | Strong Buy | 4 | 25.58% | 49.46% | 91.75% | 74.18% | |||
| NAGE | NIAGEN BIOSCIENCE INC | $594.79M | $7.65 | $9.03 | 18.08% | Strong Buy | 3 | 20.03% | 35.96% | 45.54% | 30.75% | |||
| SRPT | SAREPTA THERAPEUTICS INC | $7.07B | $72.88 | $143.46 | 96.85% | Buy | 13 | 34.09% | 86.80% | 110.89% | 42.75% | |||
| SPRY | ARS PHARMACEUTICALS INC | $1.24B | $12.60 | $28.75 | 128.17% | Strong Buy | 4 | 59.45% | 56.74% | 56.68% | 41.45% | |||
| KRYS | KRYSTAL BIOTECH INC | $5.39B | $187.10 | $222.80 | 19.08% | Strong Buy | 5 | 41.68% | 61.51% | 44.73% | 40.09% | |||
| GYRE | GYRE THERAPEUTICS INC | $822.85M | $8.79 | N/A | N/A | N/A | N/A | 49.51% | 132.23% | 428.74% | 216.48% | |||
| RIGL | RIGEL PHARMACEUTICALS INC | $339.04M | $18.98 | $36.80 | 93.89% | Buy | 5 | 12.31% | 31.54% | 1,733.05% | 34.75% | |||
| HALO | HALOZYME THERAPEUTICS INC | $7.86B | $63.82 | $66.00 | 3.42% | Buy | 5 | 19.26% | 29.31% | 297.54% | 52.46% | |||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $1.90B | $33.21 | $53.71 | 61.74% | Strong Buy | 7 | 17.47% | 31.24% | 63.48% | 41.87% | |||
| VCEL | VERICEL CORP | $2.32B | $46.42 | $63.80 | 37.44% | Strong Buy | 5 | 25.85% | 78.45% | 33.55% | 22.63% | |||
| RPRX | ROYALTY PHARMA PLC | $18.19B | $31.56 | $40.00 | 26.74% | Strong Buy | 1 | 19.38% | 62.05% | 30.52% | 17.32% | |||
| NVO | NOVO NORDISK A S | $320.27B | $71.73 | $132.50 | 84.72% | Strong Buy | 2 | 16.13% | 19.77% | 129.45% | 39.88% | |||
| CPRX | CATALYST PHARMACEUTICALS INC | $3.05B | $25.15 | $33.20 | 32.01% | Strong Buy | 5 | 13.01% | 19.49% | 44.40% | 37.94% | |||
| EXEL | EXELIXIS INC | $10.36B | $37.01 | $37.59 | 1.56% | Buy | 17 | 9.78% | 21.21% | 50.38% | 38.36% | |||
| MNKD | MANNKIND CORP | $1.54B | $5.06 | $9.50 | 87.75% | Strong Buy | 2 | 15.08% | 46.28% | -173.34% | 34.69% | |||
| INCY | INCYTE CORP | $11.86B | $61.26 | $74.57 | 21.73% | Hold | 14 | 9.75% | 258.98% | 50.55% | 32.01% | |||
| ADMA | ADMA BIOLOGICS INC | $4.68B | $19.70 | $25.33 | 28.59% | Strong Buy | 3 | 20.25% | 10.07% | 98.04% | 70.02% | |||
| MDXG | MIMEDX GROUP INC | $1.13B | $7.64 | $13.00 | 70.16% | Strong Buy | 1 | 12.33% | 33.50% | N/A | N/A | |||
| TECH | BIO-TECHNE CORP | $9.39B | $59.38 | $78.83 | 32.76% | Buy | 6 | 6.22% | 40.21% | N/A | N/A | |||
| VCYT | VERACYTE INC | $2.42B | $31.05 | $42.67 | 37.41% | Buy | 9 | 10.27% | 71.19% | 7.69% | 6.95% | |||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $7.95B | $130.88 | $188.67 | 44.15% | Strong Buy | 12 | 5.54% | 31.66% | N/A | N/A | |||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $13.64B | $71.48 | $92.33 | 29.17% | Buy | 15 | 10.05% | 31.97% | N/A | N/A | |||
| ACAD | ACADIA PHARMACEUTICALS INC | $2.84B | $17.03 | $24.17 | 41.91% | Buy | 6 | 10.47% | 5.04% | 51.97% | 32.06% | |||
| GMAB | GENMAB A | $12.99B | $19.62 | $42.50 | 116.62% | Strong Buy | 4 | 18.38% | 13.02% | 4.49% | 3.60% | |||
| UTHR | UNITED THERAPEUTICS CORP | $13.96B | $310.82 | $420.86 | 35.40% | Strong Buy | 7 | 6.19% | 1.96% | 23.91% | 20.92% | |||
| REGN | REGENERON PHARMACEUTICALS INC | $69.98B | $640.14 | $944.32 | 47.52% | Buy | 19 | 5.81% | 4.26% | 22.23% | 17.28% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.